À§¾Ï ÁøÇà Ç¥ÁöÀڷμ Ç÷¾× ³» Intercellular Adhesion Molecule-1(ICAM-1)°ú Vascular Cell Adhesion Molecule-1 (VCAM-1)ÀÇ µ¿½Ã ¹ßÇö
Synchronous Expression of Circulating Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) During Gastric Cancer Progression
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Èñö
¹ÚÁØ¿À/¶ó¼±¿µ/Á¤Çöö/°ø¼öÁ¤/±èÃæ¹è/±èÁÖÇ×/³ëÀç°æ/¹ÎÁø½Ä
KMID : 0360319970290010081
Abstract
¼·Ð
Á¾¾çÀÇ Ä§À±°ú ÀüÀÌ °úÁ¤¿¡´Â Á¾¾ç¼¼Æ÷¿Í ÇÕÂøºÐÀÚµé(adhesion molecule)»çÀÌÀÇ µ¿ÀûÀÎ
´Ù´Ü°è »óÈ£ÀÛ¿ëÀÌ ÇÊ¿äÇÏ´Ù. ¾Ï¼¼Æ÷¿Í Ç÷°ü³»ÇǼ¼Æ÷¿ÍÀÇ °áÇÕ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ÇÕÂø
ºÐÀÚ´Â Å©°Ô seletin, cadherin ¹× immunoglobulin superfamily(IGSF)·Î ºÐ·ùµÈ´Ù. ƯÈ÷ Ç÷°ü
³»ÇǼ¼Æ÷¿Í Á¾¾ç¼¼Æ÷ÀÇ °·ÂÇÑ °áÇÕ°ú ³»ÇǼ¼Æ÷¸¦ ÅëÇÑ ¾Ï¼¼Æ÷ÀÇ À̵¿(transendothelial
migration)ÀÌ Á¾¾çÀüÀÌ¿¡ Áß¿äÇϸç ÀÌ °úÁ¤¿¡ ÀÛ¿ëÇÏ´Â ÇÕÂøºÐÀÚ°¡ IGSF±ºÀ¸·Î intercellular
adhesion molecule-1(ICAM-1; CD54)°ú vascular cell adhension molecule-1(VCAM-1;
CD106)ÀÌ ¿©±â¿¡ Æ÷ÇԵȴÙ. ICAM-1Àº cytokine¿¡ ÀÇÇØ À¯µµµÇ´Â ÇÕÂøºÐÀÚ·Î ºÐÀÚ·®ÀÌ
70-100kDÀÎ ´ç´Ü¹éÀÌ´Ù. ÀÌ´Â Á¾¾ç¼¼Æ÷ »Ó ¾Æ´Ï¶ó Ç÷°ü³»ÇǼ¼Æ÷, Á¶Á÷°Å´ë¼¼Ç¥, ´ÜÇÙ±¸, B
¼¼Æ÷, È°¼ºÈµÈ T¼¼Æ÷ ¹× ÀÓÆÄÀý ¹èÁß½ÉÀÇ ¼öÁö»ó ¼¼Æ÷¿Í Èä¼±ÀÇ »óÇǼ¼Æ÷, ¼¶À¯¸ð¼¼Æ÷µî¿¡
¼ ±¤¹üÀ§ÇÏ°Ô Ç¥ÇöµÈ´Ù. ¥â2 intergrin±ºÀÎ luekocyte function associated
antigen-1(LFA-1, CD11a/CD18)°ú complement receptor type-3(CR-3, MAC-1,
CD11b/CD18)°¡ ÁÖ¿ä ligand·Î ÀÛ¿ëÇϸç, interleukin-1¥â, tumor necrosis factor-¥á,
interferon-¥ô(INF-¥ô)¿Í ¼¼±ÕÀÇ lipopolysaccharide, phorbol myristate acetate, retinoic acid
µîÀÌ ICAM-1ÀÇ Ç¥ÇöÀ» À¯µµ ¶Ç´Â Áõ°¡½ÃŲ´Ù. Á¾¾ß¿¡¼´Â ¾Ç¼º¸²ÇÁÁ¾°ú ´ëÀå¾Ï, ½ÅÀå¾Ï,
ÃéÀå¾Ï, °£¾Ï°ú °°Àº ¼±¾Ï Á¶Á÷ »Ó ¾Æ´Ï¶ó ¾Ï¼¼Æ÷ ÁÖÀ§ÀÇ °£Áú°ú Á¾¾ç ħÀ±¸²ÇÁ±¸¿¡¼µµ
ICAM-1ÀÇ ¹ßÇöÀÌ °üÂûµÈ´Ù. ÇöÀç±îÁö ICAM-1°ú Á¾¾çº´¸®¿ÍÀÇ ¶Ñ·ÇÇÑ °ü°è´Â ¾ÆÁ÷ È®¸²µÇ
¾î ÀÖÁö ¾ÊÀ¸¸ç, ¾Ç¼º Èæ»öÁ¾¿¡¼ ICAM-1ÀÇ ¹ßÇö Áõ°¡°¡ Á¾¾ßÀÇ ÀüÀÌÀ§Çèµµ Áõ°¡¿Í ¹«º´
»ýÁ¸À² °¨¼Ò¿Í ¿¬°üÀÌ ÀÖÀ½ÀÌ º¸°íµÇ¾ú´Ù. VCAM-1ºÐÀÚ·®ÀÌ 90kDÀÇ ´ç´Ü¹éÀ¸·Î 7°³ÀÇ
immunoglobulin domainÀ» °¡Áö°í ÀÖ°í intergrin ¥â1 ±ºÀÎ very late antigen(VLA)-4¿¡ ÀÇ
ÇØ ÀνĵȴÙ. ÁÖ·Î Ç÷°ü³»ÇǼ¼Æ÷¿¡¼ Ç¥ÇöµÇ¾î ¸²ÇÁ±¸¿Í ´ÜÇÙ±¸ÀÇ °áÇÕÀ» ¸Å°³ÇÏ¸ç ¸²ÇÁ¼±
ÀÇ ¼öÁö»ó ¼¼Æ÷, ½ÅÀåÀÇ º®Ãø »çÇÇ, Á¶Á÷ ´ë½Ä¼¼Æ÷¿¡¼µµ °üÂûµÈ´Ù. ¸²ÇÁ±¸°ú Jy¼¼Æ÷¿¡¼ ¹è
¾ç ½Ã¿¡ ICAM-1ÀÌ ¿ëÇØµÈ ÇüÅ·Π¼¼Æ÷ ¿Ü·Î À¯¸®µÊÀÌ °üÂûµÇ¾úÀ¸¸ç, enzyme-linked
immunosorbent assay(ELISA)¸¦ ÀÌ¿ëÇØ ¿°Áõ¼º Áúȯ°ú ¾ÏȯÀÚÀÇ Ç÷û¿¡¼ circulation
ICAM-1(cICAM-1)À» Á¤·® ÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ÀÓ»óÀûÀ¸·Î cICAMÀÇ ¹ßÇöµµ°¡ ¾Ç¼ºÈæ»ö
Á¾°ú °£¾Ï¿¡¼ ¾ÏÀÇ ÁøÇà°ú »ó°ü°ü°è°¡ ÀÖ°í »ýÁ¸À²ÀÇ °¨¼Ò¿Í ¿¬°üµÇ¾î ¿¹ÈÄ ÆÇÁ¤ÀÇ Ç¥ÁöÀÚ
·Î »ç¿ëÇÒ ¼ö ÀÖÀ½ÀÌ º¸°íµÇ¾ú´Ù. ¶ÇÇÑ À§¾Ï, ÃéÀå¾Ï, ´ëÀå¾Ï, ´ã³¶¾Ï µîÀÇ ¼±¾Ï¿¡¼ cICAM
ÀÇ ¹ßÇö°ú °£ ÀüÀÌ »çÀÌ¿¡ »ó°ü°ü°è°¡ ÀÖÀ½ÀÌ º¸°íµÇ¾ú´Ù. Circulating VCAM-1
(cVCAM-1)Àº ¹è¾ç ½Ã »çÀÌÅäÄ«Àο¡ ÀÇÇØ È°¼ºÈµÈ Ç÷°ü³»ÇǼ¼Æ÷¿¡¼ ÁÖ·Î ºÐºñµÈ´Ù. Ç÷û
³»ÀÇ CVCAMÄ¡ÀÇ »ó½ÂÀº ³¼Ò¾Ï, ´ëÀå¾Ï, ½ÅÀå¾Ï, ¹æ±¤¾Ï µî¿¡¼ Á¤»ó¿¡ ºñÇØ ÃøÁ¤Ä¡°¡ Áõ
°¡Çϸç, ¾Ç¼º Èæ»öÁ¾°ú ½Å¼¼Æ÷¾Ï¿¡¼ VLA-4¿Í Ç÷°ü³»ÇǼ¼Æ÷¿¡¼ ¹ßÇöµÈ VCAM-1°úÀÇ »ó
È£ ÀÛ¿ëÀÌ Ç÷Ç༺ ÀüÀÌ¿Í °ü°è ÀÖÀ½À¸·Î º¸°íµÇ¾ú´Ù. ÀÌ·¯ÇÑ ÇÕÂøºÐÀÚÀÇ ¿ªÇÒ°ú ÀÓ»óÀû À¯
¿ë¼º¿¡ °üÇÑ ¿¬±¸°¡ ÃÖ±Ù ¿©·¯ ¾Ï Á¶Á÷¿¡¼ ÁøÇàµÇ¾úÀ¸³ª ¾ÆÁ÷±îÁö ¿ì¸® ³ª¶ó¿¡ ƯÈ÷ ¸¹°í
»ç¸Á¿øÀÎÀÇ ¼öÀ§¸¦ Â÷ÁöÇÏ´Â À§¾Ï¿¡¼ ±× ¹ßÇöµµ¿Í ¿¹ÈÄ ¿¹Ãø ÀÎÀڷμÀÇ °¡Ä¡¿¡ ´ëÇÑ ¿¬±¸
°¡ ½ÃÇàµÈ ¹Ù ¾ð´Ù. µû¶ó¼ º» ¿¬±¸¿¡¼´Â À§¾ÏȯÀÚÀÇ Ç÷û¿¡¼ ELISA¸¦ ÀÌ¿ëÇÏ¿©
cICAM-1, cVCAM-1ÀÇ ¹ßÇöÁ¤µµ¿Í Á¾¾çÁøÇà¿¡ µû¸¥ ¹ßÇöµµÀÇ Â÷À̸¦ ºÐ¼®ÇÑ ÈÄ, À§¾Ï¿¡¼
°£ ÀüÀÌ ¹× ¿¹ÈÄ ÆÇÁ¤ ¿¹ÃøÀÎÀڷμÀÇ ÀÓ»óÀû À¯¿ë¼ºÀ» Æò°¡ÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : The circulating forms of ICAM-1 (cICAM-1) and VCAM-1 (cVCAM-1) has
been reported from supernatant of cytokine activated endothelial cells, cancer cells and
from cancer patient serum even though the biological significance of the cCAMs are not
fully elucidated.
Materials and Methods : To evaluate the correlation of the expression of cICAM-1
and cVCAM-1 and prognosis in gastric cancer, we measured cICAM-1 and cVCAM-1
levels in 20 healthy volunteers and 142 gastric cancer patients' sera by ELISA assay.
Also we compared cCAMs levels with vascular endothelial growth factor (sVEGF) and
FP. Ninety-five patients were operable and 47 patients were advanced or relapsed state
at the time of the study. In 28 operable patients, we simultaneously sampled portal and
peripheral vein and measured the cCAMs.
Results : The cCAMs level and positive rate in serum increased with cancer
progression from healthy control, operable to advanced or relapsed gastric cancer. In
advanced cancer, cICAM-1 level increased with liver metastasis. The cICAM-1 level in
portal blood was correlated modestly with that in peripheral blood. And in CVCAM-1
positive subgroup, cCAM-1 level correlated with cVCAM-1 level. The peripheral
cICAM-1 level decreased in 6% compared to that of portal cICAM-1 level while
peripheral cVCAM-1 level increased in 1% compared to that of portal level. Synchronous
expression of both cCAMs was found in 58.3% of the patients with liver metastasis and
22.9% of the patients without liver metastasis (p=0.03). But, there were no correlation
between cCAMs and FP expression regardless of liver metastasis. The sVEGF level
correlated with neither cICAM-1 nor cVCAM-1 level regardless of liver metastasis. The
median disease-free and overall survival of patients with synchronous cICAM-1 and
cVCAM-1 expression was 8 months and 9 months, while in patients without
co-expression it was more than 24 months and 23 months respectively.
Conclusion : We suggest that synchronous cICAM-1 and cVCAM-1 elevation may be
a useful monitor of tumor burden and progression in gastric cancer, especially in liver
metastasis.
Å°¿öµå
Gastric Cancer; cICAM-1; cVCAM-1; Liver Metastasis;
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸